Skip to main content

Table 1 Patient profiles

From: Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin

 

Patient numbers (%)

Age average ± SD (min-max in year)

Gender Male/Female

Malignant mesothelioma

95 (48.0)

63.0 ± 11.0 (26-86)

49/46

 Epitheloid

66 (69.5)

 Mixed (Biphasic)

15 (15.8)

 Sarcomatoid

8 (8.4)

 Undefined

6 (6.3)

Metastatic cancers to pleura

56 (28.3)

61.6 ± 11.2 (34-85)

32/24

 Lung cancer

38 (67.9)

62.2 ± 11.9 (34-85)

27/11

 Other type of cancera

18 (32.1)

60.4 ± 9.7 (39-77)

5/13

Non-malignant pleural diseases

47 (23.7)

55.8 ± 17.0 (19-81)

36/11

 Benign asbestos pleurisy

20 (42.6)

61.7 ± 12.9 (40-81)

17/3

 Benign pleural diseasesb

27 (57.4)

51.4 ± 18.6 (19-77)

19/8

Total

198

  
  1. aincluding 8 cases of breast cancers, 3 lymphomas, 2 ovarian cancers, 1 stomach cancer, 1 renal cell carcinoma, 1 bladder cancer, 1 pancreatic cancer, 1 laryngeal cancer
  2. bincluding 17 cases of tuberculous pleurisies, 2 pulmonary embolisms, 2 congestive heart failures, 1 hepatic hydrothorax, 1 rheumatoid pleurisy, 1 cholesterol pleural effusion, 1 chronic renal failure, 1 pneumoconiosis, 1 parapneumonic pleurisy